BioMark Diagnostics Inc C.BUX

Alternate Symbol(s): BMKDF

Healthcare Biotechnology

BioMark Diagnostics Inc. is a liquid biopsy company. The Company is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat cancers. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. Its oncology has developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections.

CSE:BUX - Post by User

BioMark Diagnostics Inc

<< Previous

Bullboard Posts

Next >>

Post by geodcanon Jan 25, 2024 8:17pm

105 Views

Post# 35846245

SH dropping the ball on supplying reliable info

2024-01-19	Maula Bux (Rashid Ahmed)Director of Issuer	1,000	$290.00	1,218,900	SEDI
	2023-12-29	Maula Bux (Rashid Ahmed)	1,032,261	$258,065.25	4,447,411	SEDI

2024-01-19	Maula Bux (Rashid Ahmed)Director of Issuer	1,000	$290.00	1,218,900	SEDI
	2023-12-29	Maula Bux (Rashid Ahmed)	1,032,261	$258,065.25	4,447,411	SEDI

Check out the insider option and the math doesn't add up. It does show Bux trading 1000 shares to support the artificially high shareprice but a couple of hundred dollar trade and his ownership drops by 3 million shares??

My bid still is active despite it not showing on this forum today.

<< Previous

Bullboard Posts

Next >>

A Look into the Future of Chronic Pain Management